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Rat eosinophils contain eosinophil-associated ribonucleases (Ears) in their granules. Ears are thought to be synthesized as pre-forms and
stored in the granules as mature forms. However, the N-terminal amino acid of mature Ear-1 and Ear-2 is still controversial. Therefore, we
prepared two recombinant mature forms of Ear-1 and Ear-2 in which the N-terminal amino acids are Ser24 (S) [Ear-1 (S) and Ear-2 (S)] and
Gln26 (Q) [Ear-1 (Q) and Ear-2 (Q)], and analyzed their biological activities by comparing them with those of pre-form Ear-1 and pre-form
Ear-2. The four mature Ears showed RNase A activity as well as bovine pancreatic RNase A activity, but pre-Ear-1 and pre-Ear-2 showed no
RNase A activity. Mature Ear-1 (Q) and mature Ear-2 (Q) showed more potent RNase A activity than mature Ear-1 (S) and mature Ear-2 (S),
respectively. The RNase A activities of mature Ear-1 (Q) and mature Ear-2 (Q) were reduced by treatment at 96 jC for 20 min or with RNase
inhibitor. The growth of Escherichia coli was inhibited by both pre-Ears and mature Ears in a concentration-dependent manner, and was
almost completely suppressed at 1.0 AM. The bactericidal activities of mature Ear-1 (Q) and mature Ear-2 (Q) were not inhibited by RNase
inhibitor, but was increased by treatment at 96 jC for 20 min.
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Human eosinophils contain four major cationic proteins,
major basic protein (MBP) [1], eosinophil peroxidase [2],
eosinophil cationic protein (ECP) [3] and eosinophil-derived
neurotoxin (EDN) [4–6], in their granules. The granule
proteins released from eosinophils in response to various
stimuli including IgG and IgA are thought to play a
significant role in the pathogenesis of allergic inflammation
due to their cytotoxic activity against neighboring cells such
as bronchial epithelial cells [7,8].
Human ECP is similar to EDN in molecular mass
(approximately 150 amino acids) and in amino acid
sequence (67% homology), but is more basic (isoelectric
point (pI) 10.8) than EDN (pI 8.9) [9–11]. Human ECP0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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[14,15] and bactericidal activity [16,17], yet its ribonu-
clease (RNase) A activity is relatively weak [18–20]. In
contrast, human EDN is less cytotoxic [13,17,21], but has
50–100 times more RNase A activity than ECP and has
RNase A-dependent anti-viral activity against single-
stranded RNA virus such as respiratory syncytial virus
[11,18,19,22,23]. The anti-viral activity of eosinophils is
suggested to be one of the roles of eosinophils in host
defense [22,23].
Human ECP and EDN are also named human eosino-
phil RNase 3 and RNase 2, respectively, and are members
of the human RNase A superfamily together with human
pancreatic RNase (RNase 1), RNase 4, angiogenin
(RNase 5) and RNase k6 [24,25]. The RNase A super-
family is characterized by enzymatic activity and distinc-
tive elements of the conserved primary structure, but has
divergent biological functions [25,26]. The primary struc-
ture contains six or eight structural cysteines, two cata-
lytic histidines and one catalytic lysine [17,27]. Theed.
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mice, gerbils, hamsters and rats [28–35]. Larson et al.
[28] first cloned eosinophil-associated ribonuclease (Ear)-
1 and Ear-2 from a mouse cDNA library, and presumed
that neither are orthologs of human ECP. Phylogenetic
analysis suggested that human ECP, human EDN, mouse
Ear-1 and mouse Ear-2 share an ancestral gene, and have
been generated by gene duplication in each species after
the divergence of primates and rodents [28]. After that,
additional nine functional Ears (Ear3, Ear4, Ear5, Ear6,
Ear7, Ear8, Ear9, Ear10 and Ear11) and two pseudogenes
(Ear-ps1 and Ear-ps2) were then identified in mice
[30,32–34], bringing the total number of the genes in
the mouse cluster to 13. In rats, eight Ears (rR1, rR2,
rR4/Ear-2, rR5, rR7/Ear-1, rR8, rR12 and rR14) were
cloned [29,31,32,35], suggesting that the mR cluster and
the rR cluster have evolved independently in each species
[32]. Ear genes are suggested to have evolved rapidly
with gene duplication and deactivation due to their critical
physiological role in each rodent species [33].
We have already cloned three complete nucleotide
sequences for cDNA encoding the rat eosinophil granule
proteins, MBP [31,36] (accession number D50568; DDBJ,
EMBL and NCBI nucleotide sequence databases), Ear-1
(D88586) [29,31] and Ear-2 (AB005291) [35]. Rat Ear-1
and Ear-2 are thought to be composed of two functional
domains: the signal peptide and the mature Ear. However,
the cleavage sites of signal peptides of rat Ear-1 and Ear-
2 have not been clarified. The N-terminal amino acid of
rat mature Ear-1 or rat mature Ear-2 is thought to be
Ser24, by applying the pattern of signal-sequence cleavage
sites as described by von Heijne [37]. However, Larson et
al. [28] reported that the N-terminal amino acid of these
proteins is Gln26 based on direct sequencing of mouse
Ear-1 and mouse Ear-2 purified from mouse eosinophil
granules. We have previously reported that rat pre-Ear-1
(mature Ear-1 having the signal peptide) and pre-Ear-2
(mature Ear-2 having the signal peptide) have strong
bactericidal activity against Escherichia coli (E. coli)
and Staphylococcus aureus [35]. Although the bactericidal
activity of eosinophil granule proteins has been thought to
be influenced by their pI values and the number of
arginines [9–11,33], the pI value of rat pre-Ear-2 (8.59)
having strong bactericidal activity [35] is lower than that
of human EDN (8.9) having less bactericidal activity
[13,17,21]. Therefore, it was suggested that a net positive
charge is not essential for bactericidal activity [35]. To
analyze the biological activities of rat Ear-1 and Ear-2, we
prepared six recombinant Ears; pre-forms of rat Ears (pre-
Ear-1 and pre-Ear-2), mature forms starting from Ser24
[mature Ear-1 (S) and mature Ear-2 (S)], and mature forms
starting from Gln26 [mature Ear-1 (Q) and mature Ear-2
(Q)]. We show here the difference in biological activity
between rat Ear-1 and Ear-2 by comparing six recombinant
proteins, pre-Ear-1, mature Ear-1 (S), mature Ear-1 (Q),
pre-Ear-2, mature Ear-2 (S) and mature Ear-2 (Q).2. Materials and methods
2.1. Construction of the expression vector
Total RNA was prepared from rat bone marrow cells
by acid guanidinium thiocyanate–phenol–chloroform
extraction [38]. The first strand cDNA was synthesized
from 1 Ag of RNA using M-MLV reverse transcriptase
(Gibco RBL, Gaithersburg, MD, USA) in 20 Al of
reaction mixture according to the instructions accompany-
ing the M-MLV reverse transcriptase. PCR was performed
in 50 Al of 10 mM Tris–HCl buffer (pH 8.0) containing
5 Al of a solution of cDNA transcribed from total RNA,
50 mM KCl, 1.5 mM MgCl2, 250 AM each of the
dNTPs, 0.2 AM each of the sense and the antisense
primers, and 2.5 U of Taq polymerase (Takara Shuzo,
Tokyo, Japan), using a thermal cycler (GeneAmpk PCR
Systems 2400, Perkin-Elmer, Applied Biosystems Divi-
sion, Forster City, CA, USA). The PCR primers for rat
pre-Ear-1 (signal peptide+ mature Ear-1) (sense: 5V-
GGATCCATGGGTCTGAAGCTGCTC-3V and antisense:
5V-GTCGACTACAAAGTGCTGGCACCG-3V), rat pre-
Ear-2 (signal peptide +mature Ear-2) (sense: 5V-GGATC-




mature Ear-1 (Q) (sense: 5V-GGATCCCAGCCACCAAC-
CCCTTCCCAGTGG-3V and antisense: 5V-TCTGCAGAA-
TATCCTATCCAA-3V), mature Ear-2 (S) (sense: 5V-
GGATCCTCATGCCAGCGACCAACC-3V and antisense:
5V-TCTGCAGAATCTCTCATCCAG-3V) and mature Ear-2
(Q) (sense: 5V-GGATCCCAGCGACCAACCCCTTCC-
CAGTGG-3V and antisense: 5V-TCTGCAGAATCTCT-
CATCCAG-3V) were designed according to our previous
reports [27,33]. The PCR primers for rat granulocyte-
macrophage colony stimulating factor (GM-CSF) were
(sense) 5V-GGATCCCGCACCCACCCGCTCACC-3V and
(antisense) 5V-GTCGACTCATTTCTGGACCGGCTT-3V.
PCR to amplify all sets of Ear and GM-CSF genes
consisted of 1 min denaturation at 94 jC, 1 min anneal-
ing at 57 jC, and 2 min extension at 72 jC for 35
cycles. The reactions were completed with an extension
period at 72 jC for 10 min. The PCR products were ligated
into the pGEM-T vector (Promega, Madison, WI, USA) and
introduced into E. coli strain DH5a (Toyobo, Osaka, Japan).
The subcloned cDNAs for pre-Ear-1, mature Ear-1 (S),
mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S), mature Ear-
2 (Q) and GM-CSF were cleaved with BamHI and SalI, and
each Ear and GM-CSF cDNA was excised. The cDNA
fragments were inserted into the pQE-30 vector (Qiagen,
Chatsworth, CA, USA), and introduced into E. coli strain
M15 (Qiagen) for the expression of 6His-tagged Ear or
GM-CSF. The constructs were verified by DNA sequence
analysis using a DyeDeoxyk Terminator Cycle Sequencing
Core Kit (Perkin-Elmer, Applied Biosystems Division) and
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2.2. Expression and purification of recombinant Ears
Each recombinant Ear and GM-CSF was expressed in
E. coli (M15, Qiagen) and purified using Ni-NTA resin
columns (Qiagen) according to the manufacturer’s instruc-
tions. In brief, E. coli (M15) transfected with pQE-30-pre-
Ear1, pQE-30-mature Ear-1 (S), pQE-30-mature Ear-1
(Q), pQE-30-pre-Ear-2, pQE-30-mature Ear-2 (S), pQE-
30-mature Ear-2 (Q) or pQE-30-GM-CSF was cultured at
37 jC in LB-broth [1% Bacto-Tryptone (Difco Laborato-
ries, Detroit, MI, USA), 0.5% Bacto-Yeast extract (Difco
Laboratories) and 85.5 mM NaCl] containing 100 Ag/ml
ampicillin (Meiji Seika, Tokyo, Japan) and 25 Ag/ml
kanamycin (Meiji Seika). Following the induction of
expression of each recombinant Ear at 37 jC for 4 h
by the addition of 1 mM isopropyl-h-D-thio-galactopyr-
anoside (IPTG, Takara Shuzo), the E. coli was harvested
by centrifugation at 1400 g at 4 jC for 30 min, and
lysed in phosphate-buffered saline containing 0.5% Triton
X-100. After centrifugation at 1400 g at 4 jC for 30
min, the cell pellet was solubilized with buffer A (10 mM
Tris–HCl, 6 M guanidine, 0.1 M NaH2PO4, 10 mM 2-
mercaptoethanol and 20 mM imidazole, pH 8.0) by
stirring for 1 h at room temperature. To remove the
cellular debris, the suspension was centrifuged at
10,000 g and 20 jC for 20 min, and the supernatant
was obtained. Purification of each recombinant Ear and
GM-CSF was carried out using the Ni-NTA resin col-
umns. The solublized intracellular insoluble fractions were
applied to the Ni-NTA resin columns equilibrated with
buffer A, and washed with buffer A and buffer B (10
mM Tris–HCl, 8 M urea, 0.1 M NaH2PO4, 10 mM 2-
mercaptoethanol, and 20 mM imidazole, pH 6.3).
Recombinant Ears and GM-CSF were eluted with buffer
C (10 mM Tris–HCl, 8 M urea, 0.1 M NaH2PO4, 10 mM
2-mercaptoethanol and 250 mM imidazole, pH 6.3), and
then refolded by phased-urea-removing dialysis against
dialysis buffer (10 mM Tris–HCl, 0.1 M NaH2PO4 and
stepwise descending concentrations of urea, pH 6.3). The
concentration of urea in the dialysis buffer was sequen-
tially decreased (4, 3, 2, 1, 0.1, 0.01 and 0 M). Precip-
itates developing during dialysis were removed by
centrifugation at 18,600 g at 4 jC for 20 min and the
supernatant containing recombinant rat pre-Ear-1, mature
Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S),
mature Ear-2 (Q) or GM-CSF was used for the experi-
ments.
2.3. Determination of RNase A activity
RNase A activity was determined according to the
method described by Slifman et al. [18]. The reaction
was initiated at 37 jC for the periods indicated by additionof 5 Al of yeast tRNA solution (4 mg/ml in RNase-free
water, Sigma, St. Louis, MO, USA) to 0.8 ml of 50 mM
sodium phosphate buffer (pH 7.0) containing the indicated
concentrations of each recombinant Ear or bovine pancre-
atic RNase A (Type III, Sigma) in the presence or absence
of 500 U of RNase inhibitor (RNase inhibitor, cloned,
10,000 U/ml, Invitrogen, CA, USA), and stopped by
addition of 0.5 ml of ice-cold 20 mM lanthanum nitrite
solution containing 3% (v/v) perchloric acid. After incu-
bation on ice for 15 min, the reaction mixture was
centrifuged at 10,000 g for 5 min. The absorbance of
fragmented tRNA in the supernatant was measured at
260 nm using a spectrophotometer (DU7500, Beckman
Coulter, CA, USA). In some experiments, recombinant
Ears and pancreatic RNase A were heated at 96 jC for
20 min and then used.
2.4. Determination of bactericidal activity
The bactericidal activity of each purified Ear against E.
coli strain LE392 (Stratagene, La Jolla, CA, USA) was
determined according to a procedure described previously
[35]. In brief, a single colony of E. coli (LE392) maintained
on LB-agar plates was inoculated into 10 ml of LB-broth
and cultured at 37 jC for 16 h. Then, 0.1 ml of this
intermediate culture was diluted with 5 ml of fresh LB-
broth and incubated for an additional 2 h at 37 jC. A portion
of this mid-logarithmic phase culture was washed with 10
mM sodium phosphate buffer (pH 7.4), and 1107 bacteria
were incubated with various concentrations of each Ear, 1
AM bovine pancreatic RNase A or 0.3 AM GM-CSF in 0.1
ml of 10 mM Tris–HCl (pH 6.3) containing 0.1 M
NaH2PO4 and 1% LB-broth. After incubation for 2 h at
37 jC, 0.1 ml of the sample was diluted with 10 mM
sodium phosphate buffer (pH 7.4), serially spread on the
nutrient agar plates, and incubated for 12 h at 37 jC to allow
full colony development. The colonies on each plate were
then enumerated, and the number of bacterial colony-form-
ing units (CFU) [16] was calculated. In some experiments,
recombinant Ears were heated at 96 jC for 20 min and then
used.
2.5. Statistical analysis
The statistical significance of the results was analyzed
using Dunnett’s test for multiple comparisons and Student’s
t test for unpaired observations.3. Results
3.1. Expression and purification of recombinant rat Ear
Recombinant rat pre-Ear-1, mature Ear-1 (S), mature Ear-
1 (Q), pre-Ear-2, mature Ear-2 (S) and mature Ear-2 (Q)
were expressed as N-terminal 6His-tagged proteins in E.
Table 1
Amino acid sequences of the N-terminal region of rat Ear-1 and Ear-2
The pI values and number of arginines of rat pre-Ear-1, mature Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S) and mature Ear-2 (Q) are shown. The
number of amino acids is indicated on top of the sequences. The pI value of each 6His-tagged recombinant protein is also indicated.
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value as the corresponding intact protein (Table 1). These
proteins were purified from the lysate of E. coli (M15) usingFig. 1. SDS-PAGE analysis of the expression and purification of pre-Ear-1, mature
(Q). The expression of each recombinant protein was induced by IPTG and the pro
extracted from E. coli prior to addition of IPTG; lane 2: total cell lysates 4 h after
Purified recombinant Ear proteins are indicated by arrowheads.the Ni-NTA resin column under denaturing conditions.
SDS-PAGE analysis of the lysates of E. coli transfected
with pQE-30-pre-Ear-1, pQE-30-mature Ear-1 (S), pQE-30-Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S) and mature Ear-2
tein was purified using the Ni-NTA resin column. Lane 1: total cell lysates
addition of IPTG; lane 3: each Ear purified with the Ni-NTA resin column.
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(S) or pQE-30-mature Ear-2 (Q) revealed that the expression
of approximately 18-kDa proteins was induced more prom-
inently by the addition of IPTG (Fig. 1, lane 2) than by no
addition of IPTG (Fig. 1, lane 1). Recombinant rat pre-Ear-
1, mature Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature
Ear-2 (S) and mature Ear-2 (Q) were purified with the Ni-
NTA resin column (Fig. 1, lane 3).
3.2. RNase A activities of recombinant rat Ears
To clarify whether the recombinant rat pre-Ear-1, mature
Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S) and
mature Ear-2 (Q) have RNase A activity, yeast tRNA was
incubated with each recombinant rat Ear and the fragmen-
tation of yeast tRNA was determined. When 0.3 AM of
bovine pancreatic RNase A was incubated as a positive
control, the fragmentation of yeast tRNAwas induced at 0.5
min reaching a plateau (Fig. 2A). Significant fragmentationFig. 2. Time-course of ribonuclease A activities of pre-Ear-1, mature Ear-1
(S), mature Ear-1 (Q), pre-Ear-2, mature Ear-2 (S) and mature Ear-2 (Q).
(A) Yeast tRNA (20 Ag) was incubated at 37 jC for the periods indicated in
the presence of 0.3 AM of mature Ear-1 (S) (closed circles), mature Ear-1
(Q) (open circles), mature Ear-2 (S) (closed squares), mature Ear-2 (Q)
(open squares) or bovine pancreatic RNase A (closed triangles). (B) Yeast
tRNA (20 Ag) was incubated at 37 jC for the periods indicated in the
presence of 0.3 AM of pre-Ear-1 (closed diamonds), pre-Ear-2 (open
diamonds) or bovine pancreatic RNase A (closed triangles). Open triangles
indicate that yeast tRNAwas incubated in the control buffer containing the
vehicle. Values are the means from 3 samples with S.E.M. shown by
vertical bars. Where bars are not shown, they are within the symbol.
Statistical significance; ** P < 0.01, *** P < 0.001 vs. corresponding
control.
Fig. 3. Ribonuclease A activities of mature Ear-1 (Q) and mature Ear-2
(Q). Yeast tRNA (20 Ag) was incubated for 10 min at 37 jC in the
presence of the indicated concentrations of mature Ear-1 (Q) or mature
Ear-2 (Q). Values are the means from 3 samples with S.E.M. shown by
vertical bars. Statistical significance; *** P< 0.001 vs. corresponding
control.of yeast tRNA was induced at 1 min by mature Ear-1 (S),
and at 0.5 min by mature Ear-1 (Q), mature Ear-2 (S) and
mature Ear-2 (Q) at 0.3 AM, and RNase A activity was
increased time-dependently (Fig. 2A). After 10-min incuba-Table 2
Effects of heat-treatment or RNase inhibitor on RNase A activities of
mature Ear-1 (Q), mature Ear-2 (Q) and RNase A
Treatment RNase A activity
(OD260) ( 10 3)
Mature Ear-1 (Q) 46F 1
96 jC for 20 min 19F 2***
RI (500 U) 21F1***
Mature Ear-2 (Q) 500F 35
96 jC for 20 min 233F 10##
RI (500 U) 46F 1###
RNase A 580F 6
96 jC for 20 min 70F 7yyy
RI (500 U) 60F 1yyy
RI (500 U) 13F 1
Yeast tRNA was incubated for 10 min at 37 jC in the presence or absence
of 0.1 AM of intact or heat-treated mature Ear-1 (Q), mature Ear-2 (Q) and
RNase A with or without 500 U of RNase inhibitor (RI). Values are the
means from three samples with S.E.M. Statistical significance:
***P< 0.001 vs. intact mature Ear-1 (Q); ##P< 0.01, ###P < 0.001 vs. intact
mature Ear-2 (Q); yyyP< 0.001 vs. intact RNase A.
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the same activity as bovine pancreatic RNase A (Fig. 2A).
RNase A activity of mature Ear-2 was stronger than that of
mature Ear-1 during 10-min incubation (Fig. 2A). Mature
Ear-1 (Q) and mature Ear-2 (Q) showed more potent RNase
A activity than mature Ear-1 (S) and mature Ear-2 (S),
respectively (Fig. 2A). No significant RNase A activity was
detected at 0.3 AM of pre-Ear-1 or pre-Ear-2 during 15 min
incubation (Fig. 2B). Significant RNase A activity was
detected for mature Ear-1 (Q) at 0.03 AM and above, and
mature Ear-2 (Q) at 0.001 AM and above, and the activity
was increased in a concentration-dependent manner up to
1.0 AM (Fig. 3). The RNase A activity of mature Ear-2 (Q)
was 8.3 times that of mature Ear-1 (Q) at 0.1 AM (Fig. 3).
On treatment at 96 jC for 20 min or 500 U of RNase
inhibitor, the RNase A activities of mature Ear-1 (Q) and
mature Ear-2 (Q) after 10-min incubation were decreased byFig. 4. Effects of pre-Ear-1, mature Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, m
(LE392) were incubated for 2 h at 37 jC in the presence of the indicated conc
(D) pre-Ear-2, (E) mature Ear-2 (S) and (F) mature Ear-2 (Q). Colony-forming u
determined. Values are the means from 5 samples with S.E.M. shown by vertic
corresponding control.more than 55% (Table 2). Bovine pancreatic RNase A
activity was also decreased by heat treatment or RNase
inhibitor (Table 2).
3.3. Bactericidal activities of recombinant rat Ears
E. coli (LE392) was incubated at 37 jC for 2 h in the
presence of various concentrations of each recombinant rat
pre-Ear-1, mature Ear-1 (S), mature Ear-1 (Q), pre-Ear-2,
mature Ear-2 (S) or mature Ear-2 (Q). The number of colony
forming units of E. coli (LE392) determined during the
following 12-h incubation was decreased by the 2-h treat-
ment with these recombinant Ears in a concentration-
dependent manner at 0.1–1.0 AM, and almost zero at 1.0
AM (Fig. 4). The growth of E. coli (LE392) was not
suppressed by 1.0 AM of bovine pancreatic RNase A or
0.3 AM of 6His-tagged GM-CSF (Table 3). Followingature Ear-2 (S) and mature Ear-2 (Q) on the growth of E. coli. E. coli
entrations of (A) pre-Ear-1, (B) mature Ear-1 (S), (C) mature Ear-1 (Q),
nits of E. coli remaining after exposure to purified Ear protein were then
al bars. Statistical significance: * P < 0.05, ** P < 0.01, *** P < 0.001 vs.
Table 3
Effects of heat-treatment on bactericidal activities of mature Ear-1 (Q),
mature Ear-2 (Q), RNase A and GM-CSF
Treatment Percentage of CFUs
remaining
None 100.0F 5.1
Mature Ear-1 (Q) 49.3F 4.3***
96 jC for 20 min 6.2F 0.4***, ###
Mature Ear-2 (Q) 55.0F 2.1***
96 jC for 20 min 24.0F 0.8***, yyy
RNase A 96.5F 4.6
GM-CSF 89.2F 1.0
E. coli (LE392) were incubated for 2 h at 37 jC in the presence or absence
of 0.3 AM of intact mature Ear-1 (Q), intact mature Ear-2 (Q), heat-treated
mature Ear-1 (Q), heat-treated mature Ear-2 (Q), 1 AM bovine pancreatic
RNase A or 0.3 AM GM-CSF. Colony-forming units of E. coli (LE392)
remaining after exposure to these proteins were then enumerated. Values are
the means from four to five samples with S.E.M. Statistical significance:
***P < 0.001 vs. control, ###P < 0.001 vs. intact mature Ear-1 (Q),
yyyP < 0.001 vs. intact mature Ear-2 (Q).
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mature Ear-1 (Q) and Ear-2 (Q) were significantly increased
(Table 3).4. Discussion
In the present study, we prepared recombinant rat pre-
Ear-1, mature Ear-1 (S), mature Ear-1 (Q), pre-Ear-2, mature
Ear-2 (S) and mature Ear-2 (Q) using a procaryotic expres-
sion system (Table 1 and Fig. 1), and showed the following
findings: First, the RNase A activities of mature Ear-1 (Q)
and mature Ear-2 (Q) are stronger than that of mature Ear-1
(S) and mature Ear-2 (S). Second, mature Ear-2 has more
potent RNase A activity than mature Ear-1. Third, pre-forms
of Ears having signal peptide have no RNase A activity but
possess bactericidal activity against E. coli (LE392). And
fourth, the bactericidal activity is almost the same between
pre-Ear-1 and pre-Ear-2, and among the pre-form, mature
(Q) form and mature (S) form for each Ear.
In eosinophil ribonucleases, six or eight structural cys-
teines, two catalytic histidines and one catalytic lysine are
conserved in common with other members of the RNase A
superfamily [17,27]. However, it is reported that a post-
translationally modified form of EDN containing four amino
acid residues from  4 to  1 (Ser–Leu–His–Val) in its
signal peptide has less RNase activity than EDN with a
different catalytic efficiency, but a similar affinity for sub-
strate [39,40]. As shown in Fig. 2A, the RNase A activity of
the mature (Q) form was stronger than that of the mature (S)
form in both rat Ear-1 and Ear-2. Mature Ear (S) forms
contain two more amino acids, serine and cysteine, in the N-
terminal region than mature (Q) forms, and have a total of
nine cysteine residues. This additional cysteine residue in
mature Ear (S) forms might prevent the intramolecular
formation of structural disulfide bonds required for the
expression of RNase A activity, thus the RNase A activityof mature (S) forms is weaker than that of mature (Q) forms.
As the pre-Ear-1 and pre-Ear-2 showed no RNase A activity
(Fig. 2B), addition of amino acids to the N-terminal of
mature Ears might inhibit the affinity of the substrate to the
catalytic site.
Larson et al. [28] suggested that mouse Ear-1 and Ear-2
have been generated by gene duplication after the separation
of rodents and primates. Singhania et al. [32] also suggested
that the Ear family expanded independently in rats and mice.
The evolutionary process created differences in the retention
of a common ancestral gene among species [28,32]. The
substitution of amino acids from the ancestral protein (from
Arg64 to Ser and from Thr132 to Arg in EDN, and from
Arg64 to His in ECP) is suggested to contribute to the
difference in RNase A activities of EDN and ECP [41].
Alignment of the amino acid sequences of eosinophil
ribonucleases revealed that the Arg64 and Thr132 in ancestral
protein were substituted with Gly and Gly in rat Ear-1, and
Lys and Gly in rat Ear-2, respectively [33,41]. Although it is
unclear whether the substitution contributes to the difference
in RNase A activity between rat Ear-1 and Ear-2, rat Ear-2 is
suggested to have obtained stronger RNase A activity than
the ancestral protein through evolutional duplication. RNase
inhibitor and denaturation by heat treatment at 96 jC for 20
min significantly suppressed the RNase A activities of
mature Ear-1 (Q) and mature Ear-2 (Q) (Table 2), indicating
that mature Ear-1 (Q) and mature Ear-2 (Q) are sensitive to
RNase inhibitor and heat treatment like other members of
the RNase A superfamily including pancreatic RNase A
[42].
Recombinant rat pre-Ear-1 and pre-Ear-2 showed bacter-
icidal activity at concentrations at which they did not show
RNase A activity (Figs. 2 and 4), and pancreatic RNase A at
1 AM showed no bactericidal activity (Table 3). Further-
more, the 6His-tagged GM-CSF showed no bactericidal
activity (Table 3). These findings indicate that 6His-tag
has no influence on the activity of Ears, and suggest that the
mechanism for the expression of bactericidal activity by rat
Ear-1 and Ear-2 is different from that for the expression of
RNase A activity.
Antimicrobial peptides are cationic having a small
molecular mass (1–5 kDa), and protect the host against
microorganisms by killing them [43]. The antimicrobial
peptides bind to bacterial membranes by the following
two interactions: nonpolar amino acids of the antimicrobial
peptides bind to the hydrophobic core of the microbial
membrane, and positive charges of the antimicrobial pep-
tides interact with negative charges of the microbial mem-
brane. Thus, the membrane permeability is increased and
the microbial membrane is disrupted [43,44]. Lactoferrin is
another type of antimicrobial protein with a molecular mass
of 76 kDa and pI of 8.7 [45]. Gram-negative bacteria are
killed by lactoferrin because lactoferrin destabilizes the
membrane of Gram-negative bacteria and binds to irons
essential for their growth [46]. Human ECP kills target cells
by forming transmembrane pores [12]. But human EDN has
K. Ishihara et al. / Biochimica et Biophysica Acta 1638 (2003) 164–172 171no bactericidal activity up to 5 AM at which concentration
human ECP shows bactericidal activity [17]. The different
actions of human ECP and human EDN have been proposed
to be due to the difference in the pI value and the number of
arginines in human ECP (pI 10.8, 19 arginines) and EDN (pI
8.9, 8 arginines) [9–11,33]; the cationic property being
important for the expression of antimicrobial activity. The
present study showed that the six recombinant Ears
inhibited the growth of E. coli (LE392) in almost the same
concentration-dependent manner, and complete suppression
was obtained at 1.0 AM (Fig. 4). Because pre-Ear-1, mature
Ear-1 (S) and mature Ear-1 (Q) are highly cationic and have
a large number of arginines (Table 1) like human ECP, the
mechanism of bactericidal activity of Ear-1 is suggested to
be similar to that of ECP or antimicrobial peptides. How-
ever, the pI values of pre-Ear-2, mature Ear-2 (S) and mature
Ear-2 (Q) are 8.59, 8.52 and 8.64, respectively, and the
numbers of arginines are 9, 8 and 8, respectively (Table 1).
The numbers of arginines in mature Ear-2 (S) and mature
Ear-2 (Q) are the same as that in human EDN and the pI
values of rat mature Ear-2 (S) and mature Ear-2 (Q) are
lower than that of human EDN, yet Ear-2 (S) and Ear-2 (Q)
showed the same potent bactericidal activity as Ear-1 (S)
and Ear-1 (Q). Therefore, the mechanism by which Ear-2
exerts its bactericidal activity might not depend on the pI
value and the number of arginines. Further investigation is
necessary to clarify the mechanism of bactericidal activity
of Ear-1 and Ear-2. In addition, we showed that the
bactericidal activities of mature Ear-1 (Q) and mature Ear-
2 (Q) were further enhanced by the heat treatment (Table 2).
The mechanism for the enhancement by the heat treatment
remains to be elucidated. It is suggested that Ears are able to
express strong bactericidal activity not only under normal
conditions but also when denatured, and play a critical role
in host defense.
In conclusion, rat mature Ear-2 has stronger RNase A
activity than mature Ear-1, but has almost the same bacter-
icidal activity as mature Ear-1. The addition of signal
peptides to mature Ear-1 and Ear-2 diminishes their RNase
A activity, but has no influence on their bactericidal activity.Acknowledgements
This work was supported by Grants-in-Aid for Scientific
Research (B) (14370738 to K.O.) from the Japan Society for
the Promotion of Science (JSPS).References
[1] G.J. Gleich, D.A. Loegering, J.E. Maldonado, Identification of a ma-
jor basic protein in guinea pig eosinophil granules, J. Exp. Med. 137
(1973) 1459–1471.
[2] R.L. Olsen, C. Little, Purification and some properties of myeloper-
oxidase and eosinophil peroxidase from human blood, Biochem. J.
209 (1983) 781–787.[3] I. Olsson, P. Venge, Cationic proteins of human granulocytes: II.
Separation of the cationic proteins of the granules of leukemic mye-
loid cells, Blood 44 (1974) 235–246.
[4] D.T. Durack, S.M. Sumi, S.J. Klebanoff, Neurotoxicity of human
eosinophils, Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 1437–1443.
[5] C.G.B. Peterson, P. Venge, Purification and characterization of a new
cationic protein—eosinophil protein-X (EPX)—from granules of hu-
man eosinophils, Immunology 50 (1983) 19–26.
[6] N.R. Slifman, P. Venge, C.G. Peterson, D.J. McKean, G.J. Gleich,
Human eosinophil-derived neurotoxin and eosinophil protein X are
likely the same protein, J. Immunol. 143 (1989) 2317–2322.
[7] R.I. Abu-Ghazaleh, T. Fujisawa, J. Mestecky, R.A. Kyle, G.J. Gleich,
IgA-induced eosinophil degranulation, J. Immunol. 142 (1989)
2393–2400.
[8] G.J. Gleich, E. Frigas, D.A. Loegering, D.L. Wassom, D. Steinmuller,
Cytotoxic properties of the eosinophil major basic protein, J. Immu-
nol. 123 (1979) 2925–2927.
[9] H.F. Rosenberg, S.J. Ackerman, D.G. Tenen, Human eosinophil cat-
ionic protein. Molecular cloning of a cytotoxin and helminthotoxin
with ribonuclease activity, J. Exp. Med. 170 (1989) 163–176.
[10] H.F. Rosenberg, D.G. Tenen, S.J. Ackerman, Molecular cloning of the
human eosinophil-derived neurotoxin: a member of the ribonuclease
gene family, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 4460–4464.
[11] R.L. Barker, D.A. Loegering, R.M. Ten, K.J. Hamann, L.R. Pease,
G.J. Gleich, Eosinophil cationic protein cDNA. Comparison with
other toxic cationic proteins and ribonucleases, J. Immunol. 143
(1989) 952–955.
[12] J.D. Young, C.G. Peterson, P. Venge, Z.A. Cohn, Mechanism of
membrane damage mediated by human eosinophil cationic protein,
Nature 321 (1986) 613–616.
[13] S. Motojima, E. Frigas, D.A. Loegering, G.J. Gleich, Toxicity of
eosinophil cationic proteins for guinea pig tracheal epithelium in
vitro, Am. Rev. Respir. Dis. 139 (1989) 801–805.
[14] M. Yazdanbakhsh, P.C. Tai, C.J. Spry, G.J. Gleich, D. Roos, Syner-
gism between eosinophil cationic protein and oxygen metabolites in
killing of schistosomula of Schistosoma mansoni, J. Immunol. 138
(1987) 3443–3447.
[15] K.J. Hamann, G.J. Gleich, J.L. Checkel, D.A. Loegering, J.W. McCall,
R.L. Barker, In vitro killing of microfilariae of Brugia pahangi and
Brugia malayi by eosinophil granule proteins, J. Immunol. 144 (1990)
3166–3173.
[16] R.I. Lehrer, D. Szklarek, A. Barton, T. Ganz, K.J. Hamann, G.J.
Gleich, Antibacterial properties of eosinophil major basic protein
and eosinophil cationic protein, J. Immunol. 142 (1989) 4428–4434.
[17] H.F. Rosenberg, Recombinant human eosinophil cationic protein. Ri-
bonuclease activity is not essential for cytotoxicity, J. Biol. Chem. 270
(1995) 7876–7881.
[18] N.R. Slifman, D.A. Loegering, D.J. McKean, G.J. Gleich, Ribonu-
clease activity associated with human eosinophil-derived neurotoxin
and eosinophil cationic protein, J. Immunol. 137 (1986) 2913–2917.
[19] U. Gullberg, B. Widegren, U. Arnason, A. Egesten, I. Olsson, The
cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity,
Biochem. Biophys. Res. Commun. 139 (1986) 1239–1242.
[20] S. Sorrentino, D.G. Glitz, Ribonuclease activity and substrate prefer-
ence of human eosinophil cationic protein (ECP), FEBS Lett. 288
(1991) 23–26.
[21] K.J. Hamann, R.L. Barker, D.A. Loegering, G.J. Gleich, Comparative
toxicity of purified human eosinophil granule proteins for newborn
larvae of Trichinella spiralis, J. Parasitol. 73 (1987) 523–529.
[22] J.B. Domachowske, K.D. Dyer, C.A. Bonville, H.F. Rosenberg,
Recombinant human eosinophil-derived neurotoxin/RNase 2 func-
tions as an effective antiviral agent against respiratory syncytial
virus, J. Infect. Dis. 177 (1998) 1458–1464.
[23] J.B. Domachowske, K.D. Dyer, A.G. Adams, T.L. Leto, H.F. Rosen-
berg, Eosinophil cationic protein/RNase 3 is another RNase A-family
ribonuclease with direct antiviral activity, Nucleic Acids Res. 26 (1998)
3358–3363.
K. Ishihara et al. / Biochimica et Biophysica Acta 1638 (2003) 164–172172[24] H.F. Rosenberg, The eosinophil ribonucleases, Cell. Mol. Life Sci. 54
(1998) 795–803.
[25] G. D’Alessio, J.F. Riordan, in: G. D’Alessio, J.F. Riordan (Eds.), Ri-
bonucleases: Structures and Functions, Academic Press, San Diego,
1997.
[26] J.J. Beintema, Introduction: the ribonuclease A superfamily, Cell.
Mol. Life Sci. 54 (1998) 763–765.
[27] H.F. Rosenberg, K.D. Dyer, Eosinophil cationic protein and eosino-
phil-derived neurotoxin. Evolution of novel function in a primate
ribonuclease gene family, J. Biol. Chem. 270 (1995) 21539–21544.
[28] K.A. Larson, E.V. Olson, B.J. Madden, G.J. Gleich, N.A. Lee, J.J.
Lee, Two highly homologous ribonuclease genes expressed in mouse
eosinophils identify a larger subgroup of the mammalian ribonu-
clease superfamily, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
12370–12375.
[29] T. Nittoh, M. Hirakata, S. Mue, K. Ohuchi, Identification of cDNA
encoding rat eosinophil cationic protein/eosinophil-associated ribonu-
clease, Biochim. Biophys. Acta 1351 (1997) 42–46.
[30] D. Batten, K.D. Dyer, J.B. Domachowske, H.F. Rosenberg, Molecular
cloning of four novel murine ribonuclease genes: unusual expansion
within the ribonuclease A gene family, Nucleic Acids Res. 25 (1997)
4235–4239.
[31] T. Nittoh, M. Hirakata, S. Mue, K. Ohuchi, Identification of cDNA for
rat homologues of human major basic protein and eosinophil cationic
protein, Int. Arch. Allergy Immunol. 117 (Suppl. 1) (1998) 5–9.
[32] N.A. Singhania, K.D. Dyer, J. Zhang, M.S. Deming, C.A. Bonville,
J.B. Domachowske, H.F. Rosenberg, Rapid evolution of the ribonu-
clease A superfamily: adaptive expansion of independent gene clus-
ters in rats and mice, J. Mol. Evol. 49 (1999) 721–728.
[33] J. Zhang, K.D. Dyer, H.F. Rosenberg, Evolution of the rodent eosino-
phil-associated RNase gene family by rapid gene sorting and positive
selection, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4701–4706.
[34] S.A. Cormier, K.A. Larson, S. Yuan, T.L. Mitchell, K. Lindenberger,
P. Carrigan, N.A. Lee, J.J. Lee, Mouse eosinophil-associated ribonu-
cleases: a unique subfamily expressed during hematopoiesis, Mamm.
Genome 12 (2001) 352–361.
[35] M. Nakajima, M. Hirakata, T. Nittoh, K. Ishihara, K. Ohuchi, Ex-
pression and purification of recombinant rat eosinophil-associatedribonucleases, homologues of human eosinophil cationic protein
and eosinophil-derived neurotoxin, and their characterization, Int.
Arch. Allergy Immunol. 125 (2001) 241–249.
[36] T. Nittoh, M. Watanabe, H. Okayama, S. Misawa, Y. Isobe, H.
Hayashi, S. Mue, K. Ohuchi, Cloning of cDNA for rat eosinophil
major basic protein, Biochim. Biophys. Acta 1264 (1995) 261–264.
[37] G. von Heijne, Patterns of amino acids near signal-sequence cleavage
sites, Eur. J. Biochem. 133 (1983) 17–21.
[38] P. Chomczynski, N. Sacchi, Single-step method of RNA isolation by
acid guanidinium thiocyanate–phenol–chloroform extraction, Anal.
Biochem. 162 (1987) 156–159.
[39] R. Sakakibara, K. Hashida, N. Tominaga, K. Sakai, M. Ishiguro, S.
Imamura, F. Ohmatsu, E. Sato, A putative mouse oocyte maturation
inhibitory protein from urine of pregnant women: N-terminal se-
quence homology with human nonsecretory ribonuclease, Chem.
Pharm. Bull. 39 (1991) 146–149.
[40] C. Chang, D.L. Newton, S.M. Rybak, A. Wlodawer, Crystallographic
and functional studies of a modified form of eosinophil-derived neu-
rotoxin (EDN) with novel biological activities, J. Mol. Biol. 317
(2002) 119–130.
[41] J. Zhang, H.F. Rosenberg, Complementary advantageous substitu-
tions in the evolution of an antiviral RNase of higher primates, Proc.
Natl. Acad. Sci. U. S. A. 99 (2002) 5486–5491.
[42] S.E. Zale, A.M. Klibanov, Why does ribonuclease irreversibly inacti-
vate at high temperatures? Biochemistry 25 (1986) 5432–5444.
[43] W. van’t Hof, E.C. Veerman, E.J. Helmerhorst, A.V. Amerongen,
Antimicrobial peptides: properties and applicability, Biol. Chem.
382 (2001) 597–619.
[44] K. Matsuzaki, Why and how are peptide– lipid interactions utilized
for self-defense? Magainins and tachyplesins as archetypes, Biochim.
Biophys. Acta 1462 (1999) 1–10.
[45] N. Moguilevsky, L.A. Retegui, P.L. Masson, Comparison of human
lactoferrins from milk and neutrophilic leucocytes. Relative molecular
mass, isoelectric point, iron-binding properties and uptake by the
liver, Biochem. J. 229 (1985) 353–359.
[46] L.H. Vorland, Lactoferrin: a multifunctional glycoprotein, APMIS
107 (1999) 971–981.
